Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Translational control of mRNAs is a point of convergence for many oncogenic signals
through which cancer cells tune protein expression in tumorigenesis. Cancer cells rely on …

The PEA3 subfamily is a subgroup of the E26 transformation-specific (ETS) family. Its
members, ETV1, ETV4, and ETV5, have been found to be overexpressed in multiple …

As the most aggressive tumor, the outcome of pancreatic cancer (PACA) has not improved
observably over the last decade. Anatomy-based TNM staging does not exactly identify …

Awareness of the importance of immunity in controlling cancer development triggered
research into the impact of its key oncogenic drivers on the immune response, as well as …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Abstract p53 mutations predispose cancer cell development, promote their survival and
metastasis, and lead to ineffective therapeutic responses and unfavorable prognosis. No …